Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Septerna
Biotech
Septerna drops lead asset over side effects 4 months after IPO
Septerna stood out from last year's IPOs due to the lack of clinical data. Now, the data are in—and it’s led the biotech to abandon its lead asset.
James Waldron
Feb 18, 2025 9:43am
Why biotechs can benefit from the 'rational' IPO environment
Jan 24, 2025 10:30am
What can we learn from 2024’s biotech IPOs?
Dec 6, 2024 8:44am
Septerna goes public with upsized offering of $288M
Oct 25, 2024 10:29am
Septerna plans $158M IPO to fund readouts for GPCR pipeline
Oct 21, 2024 8:30am
GPCR firm Septerna files for IPO on strength of preclinical data
Oct 3, 2024 6:00am
